Literature DB >> 21110697

EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy.

Christian Freudlsperger1, Jeffrey R Burnett, Jay A Friedman, Vishnu R Kannabiran, Zhong Chen, Carter Van Waes.   

Abstract

IMPORTANCE OF THE FIELD: Recent advances in the understanding of the oncogenesis of head and neck squamous cell carcinomas (HNSCC) have revealed multiple dysregulated signaling pathways. One frequently altered axis is the EGFR-PI3K-Akt-mTOR pathway. This pathway plays a central role in numerous cellular processes including metabolism, cell growth, apoptosis, survival and differentiation, which ultimately contributes to HNSCC progression. AREAS COVERED IN THIS REVIEW: Books, journals, databases and websites have been searched to provide a current review on the subject. WHAT THE READER WILL GAIN: This article reviews the current understanding of EGFR-PI3K-Akt-mTOR signaling in HNSCC, including the impact of both genetic and epigenetic alterations. This review further highlights the potential of targeting this signaling cascade as a promising therapeutic approach in the treatment of HNSCC. TAKE HOME MESSAGE: Genetic alterations of several nodes within this pathway, including both genetic and epigenetic changes, leading to either oncogene activation or inactivation of tumor suppressors have frequently been implicated in HNSCC. Consequently, drugs that target the central nodes of this pathway have become attractive for molecular oriented cancer therapies. Numerous preclinical and clinical studies are being performed in HNSCC; however, more studies are still needed to better understand the biology of this pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21110697      PMCID: PMC3399735          DOI: 10.1517/14728222.2011.541440

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  112 in total

1.  Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.

Authors:  I Hostein; D Robertson; F DiStefano; P Workman; P A Clarke
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

Review 2.  Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease.

Authors:  S M Gollin
Journal:  Head Neck       Date:  2001-03       Impact factor: 3.147

Review 3.  HIF-1alpha and STAT3 client proteins interacting with the cancer chaperone Hsp90: therapeutic considerations.

Authors:  Hanna Leah Kim; Marco Cassone; Laszlo Otvos; Paraskevi Vogiatzi
Journal:  Cancer Biol Ther       Date:  2007-12-21       Impact factor: 4.742

Review 4.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Authors:  Amancio Carnero; Carmen Blanco-Aparicio; Oliver Renner; Wolfgang Link; Juan F M Leal
Journal:  Curr Cancer Drug Targets       Date:  2008-05       Impact factor: 3.428

5.  PTEN expression and methylation status in oral squamous cell carcinoma.

Authors:  Yoshinori Kurasawa; Masashi Shiiba; Megumi Nakamura; Kazuaki Fushimi; Takashi Ishigami; Hiroki Bukawa; Hidetaka Yokoe; Katsuhiro Uzawa; Hideki Tanzawa
Journal:  Oncol Rep       Date:  2008-06       Impact factor: 3.906

6.  A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.

Authors:  Joseph R Garlich; Pradip De; Nandini Dey; Jing Dong Su; Xiaodong Peng; Antoinette Miller; Ravoori Murali; Yiling Lu; Gordon B Mills; Vikas Kundra; H-K Shu; Qiong Peng; Donald L Durden
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

7.  SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.

Authors:  Sarat Chandarlapaty; Ayana Sawai; Qing Ye; Anisa Scott; Melanie Silinski; Ken Huang; Pat Fadden; Jeff Partdrige; Steven Hall; Paul Steed; Larry Norton; Neal Rosen; David B Solit
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

8.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.

Authors:  Suzanne A Eccles; Andy Massey; Florence I Raynaud; Swee Y Sharp; Gary Box; Melanie Valenti; Lisa Patterson; Alexis de Haven Brandon; Sharon Gowan; Frances Boxall; Wynne Aherne; Martin Rowlands; Angela Hayes; Vanessa Martins; Frederique Urban; Kathy Boxall; Chrisostomos Prodromou; Laurence Pearl; Karen James; Thomas P Matthews; Kwai-Ming Cheung; Andrew Kalusa; Keith Jones; Edward McDonald; Xavier Barril; Paul A Brough; Julie E Cansfield; Brian Dymock; Martin J Drysdale; Harry Finch; Rob Howes; Roderick E Hubbard; Alan Surgenor; Paul Webb; Mike Wood; Lisa Wright; Paul Workman
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

9.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Authors:  Sauveur-Michel Maira; Frédéric Stauffer; Josef Brueggen; Pascal Furet; Christian Schnell; Christine Fritsch; Saskia Brachmann; Patrick Chène; Alain De Pover; Kevin Schoemaker; Doriano Fabbro; Daniela Gabriel; Marjo Simonen; Leon Murphy; Peter Finan; William Sellers; Carlos García-Echeverría
Journal:  Mol Cancer Ther       Date:  2008-07-07       Impact factor: 6.261

Review 10.  Chromosomal imbalances in oral squamous cell carcinoma: examination of 31 cell lines and review of the literature.

Authors:  Christa Lese Martin; Shalini C Reshmi; Thomas Ried; William Gottberg; John W Wilson; Jaya K Reddy; Poornima Khanna; Jonas T Johnson; Eugene N Myers; Susanne M Gollin
Journal:  Oral Oncol       Date:  2007-08-02       Impact factor: 5.337

View more
  60 in total

1.  Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.

Authors:  Andrew J Leiker; William DeGraff; Rajani Choudhuri; Anastasia L Sowers; Angela Thetford; John A Cook; Carter Van Waes; James B Mitchell
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.

Authors:  Suresh Mohan; Robert Vander Broek; Sujay Shah; Danielle F Eytan; Matthew L Pierce; Sophie G Carlson; Jamie F Coupar; Jialing Zhang; Hui Cheng; Zhong Chen; Carter Van Waes
Journal:  Clin Cancer Res       Date:  2015-05-14       Impact factor: 12.531

3.  Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab.

Authors:  Alexandre A B A da Costa; Felipe D'Almeida Costa; Adriana R Ribeiro; Andréia P Guimarães; Ludmila T Chinen; Clóvis A P Lopes; Vladmir C C de Lima
Journal:  Int J Clin Oncol       Date:  2014-05-27       Impact factor: 3.402

Review 4.  Emerging drugs for head and neck cancer.

Authors:  Yihui Wen; Jennifer R Grandis
Journal:  Expert Opin Emerg Drugs       Date:  2015-03-31       Impact factor: 4.191

5.  Models for Predicting Stage in Head and Neck Squamous Cell Carcinoma Using Proteomic and Transcriptomic Data.

Authors:  Chanchala D Kaddi; May D Wang
Journal:  IEEE J Biomed Health Inform       Date:  2015-10-08       Impact factor: 5.772

6.  Activation of AKT is associated with metastasis of nasopharyngeal carcinoma.

Authors:  Ying Liu; Long-Hua Chen; Ya-Wei Yuan; Qi-Sheng Li; Ai-Ming Sun; Jian Guan
Journal:  Tumour Biol       Date:  2011-11-25

7.  Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer.

Authors:  Katelyn D Bothwell; Tatiana Shaurova; Mihai Merzianu; Amritha Suresh; Moni A Kuriakose; Candace S Johnson; Pamela A Hershberger; Mukund Seshadri
Journal:  Cancer Prev Res (Phila)       Date:  2015-06-22

8.  Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR).

Authors:  Christoph Garbers; Fabian Kuck; Samadhi Aparicio-Siegmund; Kirstin Konzak; Mareike Kessenbrock; Annika Sommerfeld; Dieter Häussinger; Philipp A Lang; Dirk Brenner; Tak W Mak; Stefan Rose-John; Frank Essmann; Klaus Schulze-Osthoff; Roland P Piekorz; Jürgen Scheller
Journal:  Cell Cycle       Date:  2013-09-18       Impact factor: 4.534

Review 9.  Oral epithelial stem cells - implications in normal development and cancer metastasis.

Authors:  Silvana Papagerakis; Giuseppe Pannone; Li Zheng; Imad About; Nawar Taqi; Nghia P T Nguyen; Margarite Matossian; Blake McAlpin; Angela Santoro; Jonathan McHugh; Mark E Prince; Petros Papagerakis
Journal:  Exp Cell Res       Date:  2014-05-05       Impact factor: 3.905

10.  MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway.

Authors:  Li Zhang; Heping Chen; Yueqiong Song; Qing Gu; Lu Zhang; Qin Xie; Jin Xu; Min Zhang
Journal:  Dig Dis Sci       Date:  2020-09-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.